Exploring Genomic Biomarkers for Pembrolizumab Response: A Real-World Approach and Patient Similarity Network Analysis Reveal DNA Response and Repair Gene Mutations as a Signature
Marco Filetti(Agostino Gemelli University Polyclinic), Manuela Petti(Sapienza University of Rome), Raffaele Giusti(CTO Andrea Alesini), Mario Occhipinti(Fondazione IRCCS Istituto Nazionale dei Tumori), Andrea Botticelli(Policlinico Umberto I), Elisabetta Ferretti(Sapienza University of Rome), Paolo Marchetti(Istituto Dermopatico dell'Immacolata), Pasquale Lombardi(Università Cattolica del Sacro Cuore), Fabio Scirocchi(Bambino Gesù Children's Hospital), Marianna Nuti(National Institutes of Health), Lorenzo Farina(Sapienza University of Rome), Aurelia Rughetti(Sapienza University of Rome), Gennaro Daniele(Università Cattolica del Sacro Cuore), Alessio Ugolini(The Wistar Institute), Alessio Cirillo(Sapienza University of Rome), Giuseppe Lo Russo(Fondazione IRCCS Istituto Nazionale dei Tumori), Filippo de Braud(University of Milan)
Cited by 3
Related Papers
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835
Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas
|Nature Genetics|2013|709
A spectrum of monoclonal antibodies reactive with human mammary tumor cells.
|Proceedings of the National Academy of Sciences|1981|563
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials
|The Lancet Oncology|2019|537